OM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Outset Medical (OM) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has no strong proprietary buy signal, no recent positive news catalyst, bearish moving averages, and weak near-term trend expectations. Even though analysts still keep Buy ratings, their price targets were recently cut, which shows fading conviction. For an impatient investor who does not want to wait for a better entry, this is still a hold rather than an immediate buy.
The technical picture is weak to neutral. MACD histogram is slightly negative and still below zero, RSI_6 at 60.1 is neutral, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 4.26 is near the first resistance level at 4.277, while pivot support is 3.918 and downside support sits lower at 3.559. The short-term trend model also points to weakness, with a 70% chance of -0.86% next day, -8.72% next week, and -3.99% next month. Overall, the chart does not support an aggressive long-term entry right now.
["Analysts still maintain Buy ratings from TD Cowen and Stifel.", "Options open interest skews heavily toward calls, which is mildly bullish.", "No recent negative news appeared in the past week."]
["No news catalysts in the recent week.", "Recent analyst price targets were cut: TD Cowen from $12 to $10 and Stifel from $8 to $6.", "Bearish moving average structure and negative MACD momentum.", "Historical pattern-based outlook suggests near-term downside.", "No recent hedge fund, insider, or congress trading support."]
No usable latest-quarter financial snapshot was provided due to a data error, so there is no reliable quarter-over-quarter growth assessment available here. Because of that, there is no evidence in the provided data to justify a fresh long-term buy based on fundamentals.
Analyst sentiment is still positive overall because both TD Cowen and Stifel kept Buy ratings. However, the trend in ratings is weakening because both firms lowered price targets on 2026-05-08. The Wall Street pros view is mildly constructive on the business, but the cons are more important right now: lower targets, lack of fresh catalysts, and weak technical setup. Politicians or influential figures have not recently bought or sold the stock, and there is no congress trading data in the last 90 days.
